{
    "clinical_study": {
        "@rank": "70548", 
        "arm_group": [
            {
                "arm_group_label": "ASP2151(200 mg)", 
                "arm_group_type": "Experimental", 
                "description": "once daily"
            }, 
            {
                "arm_group_label": "ASP2151(400mg)", 
                "arm_group_type": "Experimental", 
                "description": "once daily"
            }, 
            {
                "arm_group_label": "valaciclovir", 
                "arm_group_type": "Experimental", 
                "description": "1000 mg three times daily"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with\n      valaciclovir (VACV) 3000 mg in patients with herpes zoster."
        }, 
        "brief_title": "Phase III Study of ASP2151 in Herpes Zoster Patients", 
        "condition": "Herpes Zoster", 
        "condition_browse": {
            "mesh_term": "Herpes Zoster"
        }, 
        "detailed_description": {
            "textblock": "A double-blind, randomized, parallel-group study will be conducted to evaluate the efficacy\n      and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in\n      patients with herpes zoster. The efficacy will be evaluated for the primary endpoint defined\n      as, \"the proportion of subjects achieving cessation of new lesion formation by Day 4 of\n      study treatment\" to demonstrate the non-inferiority of ASP2151 to VACV. The safety will be\n      evaluated based on adverse events, laboratory tests, vital signs, and ECGs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        (1) Patients who have a rash associated with herpes zoster, and who can start receiving\n        the study drug within 72 hours after onset of the rash\n\n        Exclusion Criteria:\n\n          1. Patients who are not expected to have an adequate response to oral antiviral\n             medication\n\n          2. An extreme decline in immune function\n\n          3. Presence of serious complications\n\n          4. Patients found to meet any of the following conditions based on laboratory tests\n             performed within 14 days before informed consent:\n\n               -  AST or ALT \u2265 2.5 x upper limit of normal\n\n               -  Platelet count < lower limit of normal\n\n               -  Serum creatinine \u2265 1.5 mg/dL\n\n               -  Creatinine clearance < 50 mL/min\n\n          5. Current or previous history of malignant tumor within 5 years before informed consent\n\n          6. Diagnosis of autoimmune disease\n\n          7. Evidence of bone marrow suppression"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959841", 
            "org_study_id": "M522101-J01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ASP2151(200 mg)", 
                    "ASP2151(400mg)"
                ], 
                "description": "200 mg once daily or 400 mg once daily", 
                "intervention_name": "ASP2151", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "valaciclovir", 
                "description": "1000 mg three times daily", 
                "intervention_name": "valaciclovir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valacyclovir", 
                "Acyclovir"
            ]
        }, 
        "lastchanged_date": "October 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sapporo", 
                        "country": "Japan", 
                        "state": "Hokkaido"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nakano-Ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase III Study of ASP2151 in Herpes Zoster Patients\u2015 A Double-blind, Valaciclovir-controlled Study", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects achieving cessation of new lesion formation by Day 4 of study treatment", 
            "safety_issue": "No", 
            "time_frame": "4days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959841"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to cessation of new lesion formation", 
                "safety_issue": "No", 
                "time_frame": "29days"
            }, 
            {
                "measure": "Time to complete crusting", 
                "safety_issue": "No", 
                "time_frame": "29days"
            }, 
            {
                "measure": "Time to healing", 
                "safety_issue": "No", 
                "time_frame": "29days"
            }, 
            {
                "measure": "Time to pain resolution", 
                "safety_issue": "No", 
                "time_frame": "29days"
            }, 
            {
                "measure": "Time to virus disappearance", 
                "safety_issue": "No", 
                "time_frame": "29days"
            }
        ], 
        "source": "Maruho Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Maruho Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}